๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-06-30

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis (NCT07090330)

A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

๐Ÿ”ต Active, Not Recruiting Phase2 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Oruka Therapeutics, Inc.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Who can join: Review the eligibility criteria below.

Location: Oruka Therapeutics Investigative Site โ€” Fountain Valley, California

Age range: 18 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

  • Oruka Therapeutics Investigative Site โ€” Fountain Valley, California
  • Oruka Therapeutics Investigative Site โ€” Los Angeles, California
  • Oruka Therapeutics Investigative Site โ€” San Diego, California
  • Oruka Therapeutics Investigative Site โ€” Santa Ana, California
  • Oruka Therapeutics Investigative Site โ€” Santa Monica, California
  • Oruka Therapeutics Investigative Site โ€” Cromwell, Connecticut
  • Oruka Therapeutics Investigative Site โ€” Miami, Florida
  • Oruka Therapeutics Investigative Site โ€” Rolling Meadows, Illinois
  • Oruka Therapeutics Investigative Site โ€” Bowling Green, Kentucky
  • Oruka Therapeutics Investigative Site โ€” Rockville, Maryland
  • Oruka Therapeutics Investigative Site โ€” Boston, Massachusetts
  • Oruka Therapeutics Investigative Site โ€” Detroit, Michigan
  • Oruka Therapeutics Investigative Site โ€” New York, New York
  • Oruka Therapeutics Investigative Site โ€” New York, New York
  • Oruka Therapeutics Investigative Site โ€” Portland, Oregon
  • Oruka Therapeutics Investigative Site โ€” Norfolk, Virginia
  • Oruka Therapeutics Investigative Site โ€” Milwaukee, Wisconsin
  • Oruka Therapeutics Investigative Site โ€” Edmonton, Alberta
  • Oruka Therapeutics Investigative Site โ€” Edmonton, Alberta
  • Oruka Therapeutics Investigative Site โ€” Surrey, British Columbia
  • Oruka Therapeutics Investigative Site โ€” Hamilton, Ontario
  • Oruka Therapeutics Investigative Site โ€” London, Ontario
  • Oruka Therapeutics Investigative Site โ€” Markham, Ontario
  • Oruka Therapeutics Investigative Site โ€” Peterborough, Ontario
  • Oruka Therapeutics Investigative Site โ€” Toronto, Ontario

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Plaque Psoriasis clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—